HK1164050A1 - 取代的偶氮蒽衍生物、藥物組合物及其使用方法 - Google Patents

取代的偶氮蒽衍生物、藥物組合物及其使用方法

Info

Publication number
HK1164050A1
HK1164050A1 HK12104614.4A HK12104614A HK1164050A1 HK 1164050 A1 HK1164050 A1 HK 1164050A1 HK 12104614 A HK12104614 A HK 12104614A HK 1164050 A1 HK1164050 A1 HK 1164050A1
Authority
HK
Hong Kong
Prior art keywords
methods
pharmaceutical compositions
substituted azoanthracene
azoanthracene derivatives
derivatives
Prior art date
Application number
HK12104614.4A
Other languages
English (en)
Inventor
．米賈裡
．貝梅
．克裡森
．波裡塞蒂
．奎達
．桑索施
．邦德拉
．居澤爾
．亞拉岡塔
．戈希姆庫拉
．安德魯斯
．戴維斯
．約庫姆
．弗裡曼
Original Assignee
轉化技術製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 轉化技術製藥有限責任公司 filed Critical 轉化技術製藥有限責任公司
Publication of HK1164050A1 publication Critical patent/HK1164050A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
HK12104614.4A 2009-03-30 2012-05-10 取代的偶氮蒽衍生物、藥物組合物及其使用方法 HK1164050A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1164050A1 true HK1164050A1 (zh) 2012-09-21

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104614.4A HK1164050A1 (zh) 2009-03-30 2012-05-10 取代的偶氮蒽衍生物、藥物組合物及其使用方法

Country Status (18)

Country Link
US (3) US8383644B2 (zh)
EP (1) EP2413693B1 (zh)
JP (1) JP5755217B2 (zh)
KR (1) KR101732978B1 (zh)
CN (1) CN102378574B (zh)
AU (1) AU2010232750B2 (zh)
BR (1) BRPI1013579A2 (zh)
CA (1) CA2757084C (zh)
DK (1) DK2413693T3 (zh)
EA (1) EA023430B1 (zh)
ES (1) ES2553645T3 (zh)
HK (1) HK1164050A1 (zh)
IL (1) IL214822A (zh)
MA (1) MA33219B1 (zh)
MX (1) MX2011010347A (zh)
SG (1) SG174205A1 (zh)
TN (1) TN2011000437A1 (zh)
WO (1) WO2010114824A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2413693T3 (en) 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
WO2013059215A1 (en) 2011-10-17 2013-04-25 Biotheryx, Inc. Substituted biaryl alkyl amides
AU2014207748B2 (en) * 2013-01-17 2018-10-11 Vtv Therapeutics Llc Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
CN107072970B (zh) 2014-08-29 2021-05-25 得克萨斯州大学***董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2021523877A (ja) * 2018-05-08 2021-09-09 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストの治療的使用
CA3045644C (en) 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
WO2021196949A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202210487A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種ｇｌｐ－１受體激動劑游離鹼的製備方法
CN115667222B (zh) * 2020-05-28 2023-09-29 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
TW202206420A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 用於製備glp-1受體促效劑的中間體和方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
WO2021242807A1 (en) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Methods for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionate and hydrochloric acid salts thereof
EP4159719A1 (en) 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
TW202220985A (zh) 2020-09-01 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2022061091A1 (en) * 2020-09-21 2022-03-24 Vtv Therapeutics Llc Amorphous form of isoquinoline derivative
US20230373927A1 (en) * 2020-10-08 2023-11-23 Eli Lilly And Company 6-methoxy-3,4-dihydro-1h-isoquinolin compounds
EP4227299A1 (en) 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
EP4242202A4 (en) 2020-11-27 2024-05-15 Shenzhen Salubris Pharm Co Ltd BENZIMIDAZOLE DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JPWO2022202864A1 (zh) 2021-03-24 2022-09-29
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022268152A1 (zh) 2021-06-24 2022-12-29 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
WO2023029979A1 (zh) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
CA3233453A1 (en) 2021-09-28 2023-04-06 Meimei Chen Solid composition of glp-1 receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
DE60216952T2 (de) * 2001-10-19 2007-07-05 Transtech Pharma Inc. Beta-carbolin-derivate als ptp-inhibitoren
JP2005518391A (ja) * 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
KR20050114242A (ko) * 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US8466296B2 (en) * 2007-03-26 2013-06-18 Ligand Pharmaceuticals Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
DK2413693T3 (en) 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
DK2413693T3 (en) 2015-11-16
KR101732978B1 (ko) 2017-05-08
EP2413693B1 (en) 2015-09-09
MX2011010347A (es) 2011-11-29
EP2413693A1 (en) 2012-02-08
IL214822A (en) 2016-08-31
MA33219B1 (fr) 2012-04-02
WO2010114824A1 (en) 2010-10-07
BRPI1013579A2 (pt) 2020-11-03
JP5755217B2 (ja) 2015-07-29
AU2010232750A1 (en) 2011-09-08
US8987295B2 (en) 2015-03-24
SG174205A1 (en) 2011-10-28
CA2757084A1 (en) 2010-10-07
KR20120006506A (ko) 2012-01-18
EA023430B1 (ru) 2016-06-30
AU2010232750B2 (en) 2015-10-29
IL214822A0 (en) 2011-11-30
CN102378574B (zh) 2013-11-20
US20110160198A1 (en) 2011-06-30
TN2011000437A1 (en) 2013-03-27
US8383644B2 (en) 2013-02-26
CA2757084C (en) 2017-08-29
JP2012522060A (ja) 2012-09-20
US9175003B2 (en) 2015-11-03
US20150148539A1 (en) 2015-05-28
WO2010114824A8 (en) 2011-10-06
US20130096150A1 (en) 2013-04-18
EA201171197A8 (ru) 2014-10-30
EA201171197A1 (ru) 2012-04-30
EP2413693A4 (en) 2012-08-22
ES2553645T3 (es) 2015-12-10
CN102378574A (zh) 2012-03-14

Similar Documents

Publication Publication Date Title
HK1164050A1 (zh) 取代的偶氮蒽衍生物、藥物組合物及其使用方法
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
HK1194071A1 (zh) 某些***並吡嗪、其組合物及其用法
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
HK1162352A1 (zh) 某些犬尿氨酸- -單加氧酶抑制劑、藥物組合物以及使用方法
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL2281822T3 (pl) Nowe pochodne dihydroindolonów, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
PT2504331E (pt) Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
EP2536285A4 (en) SUBSTITUTED CONDENSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOUNDS AND USER METHOD THEREFOR
ZA201108458B (en) Nitrile derivatives and their pharmaceutical use and compositions
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2424533A4 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
EP2484661A4 (en) 2,3-DIHYDRO-1H-INDEN-2-YL-UREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF
EP2452681A4 (en) SALTS OF 13A- (S-) DESOXYTYLPHORININE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
ZA201200165B (en) 2-amino-2phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same
HK1173335A1 (zh) 取代的稠合咪唑衍生物、藥物組合物及其使用方法